Management of common vismodegib (VISMO)-related adverse events in patients with locally advanced basal cell carcinoma (laBCC): RegiSONIC Disease Registry Study Lacouture, M. E., Guillen, J., Kudchadkar, R., Rogers, G., Olencki, T., Tang, J., Yoo, S., Dawson, K., Mun, Y., Sekulic, A. MOSBY-ELSEVIER. 2016: AB200

View details for Web of Science ID 000412760201665